Eisai Projects Promising Sales Growth for Leqembi® by 2028

In a recent press conference held on March 25, 2025, Eisai Co., Ltd., a partner of BioArctic AB, unveiled a detailed simulation that forecasts significant sales growth for their Alzheimer's disease treatment, Leqembi® (lecanemab). According to the simulation, Eisai anticipates that Leqembi could generate between JPY 250 billion and JPY 280 billion in sales for the fiscal year ending in March 2028. This projection reflects a solid commitment to addressing the pressing needs of Alzheimer's patients globally.

The presentation outlining this simulation is accessible on Eisai's investor relations website, further highlighting the company's strategy and potential market impact. The increasing prevalence of Alzheimer's disease necessitates effective treatment options, and Leqembi stands at the forefront of this challenge.

About Leqembi®

Lecanemab is a humanized monoclonal antibody that targets aggregated soluble and insoluble forms of amyloid-beta, a significant protein implicated in Alzheimer's disease progression. It has gained approvals across various regions, including the United States, Japan, and the United Kingdom, for the treatment of mild cognitive impairment due to Alzheimer's disease as well as mild Alzheimer’s dementia. The Clinical trial data from Eisai’s Clarity AD study reinforced the efficacy of Leqembi, leading to its approval based on clear evidence of its ability to meet primary and secondary endpoints.

The U.S. Food and Drug Administration (FDA) has also approved a supplemental Biologics License Application for a less frequent intravenous maintenance dosing regimen in January 2025. Additionally, a rolling submission for a subcutaneous formulation aimed at improving patient convenience was accepted by the FDA, with expectations for a decision due by August 31, 2025.

Ongoing Clinical Trials

Eisai continues to innovate with ongoing clinical studies such as the Phase 3 AHEAD 3-45 trial targeting individuals in the preclinical stages of Alzheimer's disease. This study has completed its recruitment phase and is part of a public-private partnership aimed at advancing understanding and treatment of the disease. Another essential study is the Tau NexGen clinical trial for Dominantly Inherited Alzheimer's Disease (DIAD), showcasing lecanemab as a crucial component of the treatment regimen.

Collaborative Efforts with BioArctic

BioArctic has been a vital partner for Eisai since 2005, particularly in the development and commercialization of drugs for Alzheimer’s treatment. Their collaborative efforts have led to landmark agreements emphasizing the importance of lecanemab as a powerful treatment option. BioArctic retains rights for commercialization in the Nordic region under specific conditions while benefiting from regulatory approval payments and royalties on global sales.

The intricate relationship between BioArctic and Eisai continues to signal advancements in Alzheimer's research and treatment solutions. BioArctic, as a Swedish biopharma company, is dedicated to innovative therapies that address neurodegenerative conditions — making lecanemab a flagship product in their portfolio.

Conclusion

As the global demand for effective Alzheimer’s treatments escalates, Eisai's projections for Leqembi® not only illustrate the potential financial success but also reflect a commitment to improving patient outcomes. The anticipation of substantial sales by 2028 may set a new precedent in the market for Alzheimer's treatments while providing hope for patients and families affected by this challenging disease.